What is the role of vedolizumab in the treatment of inflammatory bowel disease (IBD)?

Updated: Oct 17, 2017
  • Author: William A Rowe, MD; Chief Editor: BS Anand, MD  more...
  • Print
Answer

Vedolizumab (Entyvio), another integrin antagonist, is approved for Crohn disease and ulcerative colitis. [100] It is specific for α4β7 integrin. Approval was based on several phase 3 clinical trials that simultaneously evaluated vedolizumab for both ulcerative colitis and Crohn disease and involved patients in nearly 40 countries. Among patients with Crohn disease who had a response to induction therapy with vedolizumab, 39.0% of those assigned to vedolizumab every 8 weeks were in clinical remission at week 52, compared with 21.6% assigned to placebo.

In patients with ulcerative colitis who had a response to vedolizumab induction, 41.8% continued to be in clinical remission at 52 weeks compared with 15.9% of patient taking placebo.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!